Figure S1 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression

Naveen Kumar Tangudu; Raquel Buj; Hui Wang; Jiefei Wang; Aidan R. Cole; Apoorva Uboveja; Richard Fang; Amandine Amalric; Baixue Yang; Adam Chatoff; Claudia V. Crispim; Peter Sajjakulnukit; Maureen A. Lyons; Kristine Cooper; Nadine Hempel; Costas A. Lyssiotis; Uma Chandran; Nathaniel W. Snyder; Katherine M. Aird

doi:10.1158/2767-9764.25738383.v1

Abstract

Knockdown of p16 or Cdkn2a in human and mouse melanoma cell lines, respectively, and DepMap dependency score data based on CDKN2A expression. Related to Figure 1.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tangudu et al. (2024) studied this question.

synapsesocial.com/papers/68e6bd48b6db64358763de74 https://doi.org/10.1158/2767-9764.25738383.v1

View at Publisher

Ask AI

Bookmark

Share

Figure S1 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression

Abstract

Discussion

Cite This Study

Figure S1 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers